These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Quality of life of patients with ADPKD-Toranomon PKD QOL study: cross-sectional study. Suwabe T, Ubara Y, Mise K, Kawada M, Hamanoue S, Sumida K, Hayami N, Hoshino J, Hiramatsu R, Yamanouchi M, Hasegawa E, Sawa N, Takaichi K. BMC Nephrol; 2013 Aug 27; 14():179. PubMed ID: 23978051 [Abstract] [Full Text] [Related]
4. Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease. Simms RJ, Thong KM, Dworschak GC, Ong AC. Nephrol Dial Transplant; 2016 Jul 27; 31(7):1130-40. PubMed ID: 26268712 [Abstract] [Full Text] [Related]
5. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Rizk D, Jurkovitz C, Veledar E, Bagby S, Baumgarten DA, Rahbari-Oskoui F, Steinman T, Chapman AB. Clin J Am Soc Nephrol; 2009 Mar 27; 4(3):560-6. PubMed ID: 19261830 [Abstract] [Full Text] [Related]
7. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE, Bae KT, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Moore CG, Flessner MF, Schrier RW, HALT-PKD Study. Am J Kidney Dis; 2014 Feb 27; 63(2):214-26. PubMed ID: 24183837 [Abstract] [Full Text] [Related]
8. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials. Neijenhuis MK, Gevers TJ, Nevens F, Hogan MC, Torres VE, Kievit W, Drenth JP. Aliment Pharmacol Ther; 2015 Sep 27; 42(5):591-8. PubMed ID: 26129925 [Abstract] [Full Text] [Related]
9. Is Regular Screening for Intracranial Aneurysm Necessary in Patients with Autosomal Dominant Polycystic Kidney Disease? A Systematic Review and Meta-analysis. Zhou Z, Xu Y, Delcourt C, Shan J, Li Q, Xu J, Hackett ML. Cerebrovasc Dis; 2017 Sep 27; 44(1-2):75-82. PubMed ID: 28502970 [Abstract] [Full Text] [Related]
10. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. Gevers TJ, Chrispijn M, Wetzels JF, Drenth JP. BMC Nephrol; 2012 Apr 04; 13():17. PubMed ID: 22475206 [Abstract] [Full Text] [Related]
11. The relationship between liver cyst volume and QOL in Japanese ADPKD patients. Muto S, Ando M, Nishio S, Hanaoka K, Ubara Y, Narita I, Kamura K, Mochizuki T, Tsuchiya K, Tsuruya K, Horie S. Clin Exp Nephrol; 2020 Apr 04; 24(4):314-322. PubMed ID: 31875934 [Abstract] [Full Text] [Related]
12. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, Rook M, van der Jagt EJ, van Goor H, Peters DJ, Navis G, de Jong PE, Gansevoort RT. Am J Kidney Dis; 2010 Nov 04; 56(5):883-95. PubMed ID: 20888104 [Abstract] [Full Text] [Related]
13. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Wetzels JF, Drenth JP. Liver Int; 2015 May 04; 35(5):1607-14. PubMed ID: 25369108 [Abstract] [Full Text] [Related]
14. Impact of liver volume on polycystic liver disease-related symptoms and quality of life. Neijenhuis MK, Kievit W, Verheesen SM, D'Agnolo HM, Gevers TJ, Drenth JP. United European Gastroenterol J; 2018 Feb 04; 6(1):81-88. PubMed ID: 29435317 [Abstract] [Full Text] [Related]
15. Frequency and clinical profile of patients with polycystic kidney disease in southern Brazil. Nunes AC, Milani V, Porsch DB, Rossato LB, Mattos CB, Roisenberg I, Barros EJ. Ren Fail; 2008 Feb 04; 30(2):169-73. PubMed ID: 18300116 [Abstract] [Full Text] [Related]
17. Sleep-Disordered Breathing in Patients with Polycystic Liver and Kidney Disease Referred for Transcatheter Arterial Embolization. Sumida K, Hoshino J, Suwabe T, Kasai T, Hayami N, Mise K, Kawada M, Imafuku A, Hiramatsu R, Hasegawa E, Yamanouchi M, Sawa N, Narui K, Takaichi K, Ubara Y. Clin J Am Soc Nephrol; 2015 Jun 05; 10(6):949-56. PubMed ID: 25825485 [Abstract] [Full Text] [Related]
18. The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease. D'Agnolo HMA, Casteleijn NF, Gevers TJG, de Fijter H, van Gastel MDA, Messchendorp AL, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JFM, Zietse R, Gansevoort RT, Drenth JPH. Am J Nephrol; 2017 Jun 05; 46(3):239-248. PubMed ID: 28881341 [Abstract] [Full Text] [Related]
19. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease. Coban M, Inci A. Int Urol Nephrol; 2018 Jul 05; 50(7):1293-1300. PubMed ID: 29654395 [Abstract] [Full Text] [Related]
20. The Risk for New-Onset Diabetes Mellitus after Kidney Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis. Cheungpasitporn W, Thongprayoon C, Vijayvargiya P, Anthanont P, Erickson SB. Can J Diabetes; 2016 Dec 05; 40(6):521-528. PubMed ID: 27184299 [Abstract] [Full Text] [Related] Page: [Next] [New Search]